



Transforming drug discovery
and development for good



Rethinking drug discovery and development



Despite numerous advances in science and technology innovation, 90% of therapies that enter clinical trials still fail, leaving patients waiting for treatments and cures.

What if there was a way to identify your “best bets” earlier, optimize resources, and dramatically increase success rates?

There is a better way with integrated in-silico model informed insights

Answering critical questions at every phase can save you years of risk and cost.



Discovery

Identify and prioritize programs and assets with the highest chance of success.



Preclinical

Translate insights to humans faster for better dosing and IND strategies.



Early Clinical

Support first-in-human dose escalation and optimize dose selection and dosing strategy.



Late Clinical

Strengthen regulatory submissions and reduce the need for additional confirmatory studies.



Market Access & Commercial

Communicate value beyond approval with data-driven label expansion, precision dosing, and real-world performance modeling.

Proven and
trusted partner

Certara customers have received **90% or more of all novel drug approvals** by the FDA from 2014 through 2024

Greater certainty and success with in-silico approaches

By integrating biosimulation, AI, predictive science and regulatory expertise, Certara eliminates costly missteps and empowers teams to make better decisions, faster. We call it model-informed drug development (MIDD) with a digital-first approach. Our customers see it as a powerful decision-support system.

10+ months

reduced per program¹

2.5X increase

in success proving proof-of-mechanism
with comprehensive modeling package²

\$5M - \$300 Million

potential savings per program³




Fig. 1
Certara Model
Informed Drug
Development
(MIDD)

One MIDD platform: Endless opportunities to transform drug discovery and development




Fig. 2 Certara solutions map

¹ Sahasrabudhe, Vaishali, et al. "Impact of Model-Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost." Clinical Pharmacology & Therapeutics, 29 Mar. 2025.

² Jansson-Löfmark, Rasmus, et al. "Translational PK/PD: A Retrospective Analysis of Performance and Impact from a Drug Portfolio." Drug Discovery Today, July 2025.

³ Based on Certara customer feedback.

Why Certara?

Certara solutions are trusted by top biopharma companies, regulatory agencies, and biotech innovators worldwide.

>100 novel drugs &
325 label claims

were approved by global regulators
using Certara technology
in lieu of clinical studies

25+

virtual patient
populations to
simulate disease
impact

Certara software was used in
bringing to market:

>100

rare disease
treatments

>380

complex biologics
programs since 2020

1,500+

experts in 30+ countries,
driving innovation

10+ years

the average tenure for
our top 30 customers



23

Global regulatory agencies
adopted Certara software

2600+

customers in more than
70 countries

Let's talk

From first-in-human trials to global regulatory approvals and post-launch, Certara solutions can help you move your science forward faster, with confidence. Start transforming your drug discovery and development processes to reduce risk and get more safe and effective medicines to the patients that need them.

[Start your transformation](#)